8-K filing — Bolt Biotherapeutics, Inc. (BOLT)
Filed: 2026-10-06 AccNo: 0001193125-26-415560 Size: 159 KB Item 1.01: Entry into a Material Definitive Agreement
Stocks · News reference
Bolt Biotherapeutics shares are trading lower after the company reported worse-than-expected Q2 financial results.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Bolt Biotherapeutics Q2 EPS $(4.57) Misses $(2.88) Estimate, Sales $5.000K Miss $500.000K Estimate
Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(4.57) per share which missed the analyst consensus estimate of $(2.88) by 58.68 percent. This is a 2.47 percent decrease over losses of $(4.46) per share